E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Localized prostate cancer after primary radical prostatectomy |
|
E.1.1.1 | Medical condition in easily understood language |
Localized prostate cancer after primary radical prostatectomy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the PSA doubling time in patients in immunotherapy group and in the control group in the treatment phase of the study. |
|
E.2.2 | Secondary objectives of the trial |
Other objectives are to compare the PSA doubling time measured in the treatment phase with the PSA doubling time prior to randomization in patients in both groups, to evaluate the PSA doubling time in patients in immunotherapy group and in the control group in the follow-up phase of the study, to monitor the incidence of adverse events, to determine the proportion of patients with a biochemical relapse, progressive increase in the PSA, objective disease progression or further anticancer therapy introduction within two years of randomization and to compare Overall Survival between the two groups.
An exploratory objective is to search for potential biomarkers that could play a role as prognostic factors, indicate the biological effect of ACI on the immune-reponse or identify a subgroup of patients profiting from cancer immunotherapy. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inc-1) Men aged ≥ 18 years
Inc-2) Histologically confirmed pT2 stage prostate cancer
Inc-3) Post-radical prostatectomy (RPE) patients
Inc-4) PSA increase which is defined as follows:
Inc-4a) After salvage radiotherapy (or RPE, if patients did not undergo salvage radiotherapy), PSA level greater than 0.020 ng/mL was detected.
Inc-4b) PSA values measured after the value greater than 0.020 ng/mL resulted in PSA doubling time (PSADT) equal or less than 12 months (It is possible to use also the initial value greater than 0.020 ng/mL for PSADT calculation). PSADT must be based on at least three increasing values (i.e. each value greater than the previous one).The interval between two subsequent measurements should be3 months (however, intervals of at least 4 weeks and at most 6 months, i.e. 26 weeks, may be accepted).If PSADT is based on more than 3 values, all the values measured between the first and the last one must be taken into account (fluctuation is allowed but the resulting trend should be increasing and fulfil the condition PSADT ≤12 months).
Fulfilment of this inclusion criterion must be confirmed by the Sponsor before randomization of the patient.
Inc-5) Patients who meet one of the following criteria:
Inc-5a) Patients who did not undergo salvage radiotherapy, who had a PSA increase as defined in Inc-4) within 2 years of RPE.
Inc-5b) Patients after the salvage radiotherapy indicated at the PSA under 1.0 ng/mL, who had a PSA increase as defined in Inc-4) at any time interval from salvage radiotherapy.
Inc-6) The following laboratory values: WBC > 4 x 10(9)/L, platelet count > 100 x 10(9)/L, Hct>30%, creatinine under 1.5 times the upper normal limit, bilirubin, AST and ALT under two times the upper limit of normal.
Inc-7) ECOG 0-2 Performance Status
Inc-8) Signed informed consent to participate in the study |
|
E.4 | Principal exclusion criteria |
E-1) Sexually active fertile men not using effective birth control, provided that their female partners are of fertile age and of child-bearing potential
E-2) Comorbidities of the patient
E-2a) HIV positivity
E-2b) Active hepatitis B or C
E-2c) Active bacterial, viral or fungal infection requiring systemic treatment
E-2d) Clinically significant cardiovascular disease,including myocardial infarction or ventricular tachyarrhythmia in previous 6 months, percutaneous coronary intervention or surgical revascularization within the previous 6 months, heart failure NYHA II-IV, known left ventricular dysfunction with ejection fraction < 40% or haemodynamically significant arrhythmias or conduction disorders, unless secured with permanent cardiac pacing.
E-2e) Pleural or pericardial effusion of any CTC grade
E-2f) Peripheral neuropathy CTC Grade ≥ 2.
E-2g) Other uncontrolled intercurrent condition, uncompensated psychiatric illness or social situation that would limit patient’s compliance.
E-2h) Patients with a history of malignancy other than non-melanoma skin cancer.
E-2i) Unresolved clinically significant urinary tract obstruction
E-2j) Active autoimmune disease requiring treatment
E-2k) History of primary immunodeficiency
E-3) Allergies and adverse drug reactions
E-3a) History of allergic reaction to a compound of the same or similar structure as medication used in this study
E-3b) History of anaphylaxis or other severe reaction following vaccination
E-4) Any other serious reason the Investigator considers the patient should not participate in the study
E-5) Any prostate cancer N and M stage other than N0 and M0.
E-6) History of prostate cancer treatment using androgen deprivation therapy at any time in the past (pharmacological treatment or bilateral orchiectomy)
E-7) PSA > 1 ng/mL prior to starting salvage radiotherapy for biochemical relapse
E-8) History of or ongoing chemotherapy for prostate cancer
E-9) Participation in another clinical trial or administration of another investigational medicinal productwithin 30 days preceding the screening
E-10) Immunotherapy other than specified in this protocol
E-11) Unauthorized concomitant medication |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the PSA doubling time in the treatment phase (from randomization to Visit V10 at Week 40). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Comparing the PSA doubling time measured in the treatment phase with the PSA doubling time prior to randomization
• Value of the PSA doubling time in the follow-up phase (from completed visit at Week 40 to 2 years from randomization)
• Incidence of adverse events
• The proportion of patients with objective disease progression (metastatic disease development -Distant Failure-DF) within 2 years of randomization
• The proportion of patients who required any further anticancer therapy within 2 years of randomization
• For the subgroup of patients who did not undergo salvage radiotherapy (only RPE), the proportion of patients who had a biochemical relapse within 2 years of randomization
• The proportion of patients who had a progressive increase in the PSA within 2 years of randomization
• Overall Survival
Exploratory endpoints
• Immune response
• Gene expression profiling, and/or expression levels of a defined set of immune or cancer-related genes, respectively |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Patient group monitored according to standard treatment procedures |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
2 years after randomization of the last subject |
2 roky po randomizaci posledního subjektu |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |